Bioconjugation Market by Product(Consumables, Instruments (Chromatography, Spectrometry)), Service (Conjugation, Analytical), Technique (Chemical, Click Chemistry), Biomolecule (Antibodies), Application (Therapeutics (ADC), R&D)-Global Forecast to 2029
생체접합 시장 규모는 2024년 52억 7,000만 달러에서 2029년 108억 6,000만 달러에 달하고, 2024년부터 2029년까지 15.6%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다.
바이오컨쥬게이션 시장의 성장에는 몇 가지 중요한 요인이 영향을 미치고 있으며, ADC와 같은 표적 치료제의 개발은 보다 정확하고 강력한 암 치료에 대한 요구가 증가함에 따라 바이오컨쥬게이션에 의해 크게 지원될 것으로 예상됩니다. 또한, 기술 개발 및 아웃소싱 서비스에 대한 관심도 높아지고 있습니다. 또한, 신흥 국가는 큰 개발 기회를 제공하고 있으며, 바이오 접합의 적용 확대가 시장을 더욱 견인할 것으로 예상됩니다.
| 조사 범위 |
| 조사 대상 연도 |
2022-2029년 |
| 기준 연도 |
2023년 |
| 예측 기간 |
2024-2029년 |
| 검토 단위 |
금액(USD) |
| 부문별 |
유형별, 기술별, 생체분자 유형별, 용도별, 최종사용자별, 공액형별, 지역별 |
| 대상 지역 |
북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카 |
2023년, 항체 접합 부문은 세계 바이오 접합 서비스 시장의 접합 유형별 부문에서 가장 큰 점유율을 차지했습니다. 항체 접합 부문이 바이오 접합 서비스 시장을 지배하는 이유는 항체 접합이 표적 치료, 특히 암 치료에 널리 사용되고 있기 때문입니다. 항체-약물 복합체(ADC)는 종양 세포의 특정 항원을 표적으로 하여 정확한 약물 전달을 가능하게 하고, 표적 외 작용과 독성을 최소화합니다. 임상시험에서 ADC의 좋은 결과와 HER2 양성 유방암을 포함한 다양한 악성 종양 치료에 대한 ADC의 승인으로 항체 기반 컨쥬게이션 서비스에 대한 수요가 증가하고 있습니다.
2023년 세계 바이오컨쥬게이션 제품 시장에서 항체 부문은 생체 분자 유형별 부문에서 가장 큰 점유율을 차지했습니다. 바이오컨쥬게이션 제품 시장에서 가장 두드러진 생체 분자 유형은 항체, 특히 단클론항체로, 표적화 정확도가 높은 항체-약물 복합체(ADC) 개발에 압도적으로 많이 사용되고 있습니다. 항체는 종양학에서 통합적으로 사용되고 있으며, 애드세트리스(Adcetris)와 카도사이라(Cadcetris)와 같은 FDA 승인 ADC 치료제로 이어졌습니다. 이러한 치료용 항체는 생체 접합 기술을 통해 세포 독성 약물과 결합하여 전신 독성을 최소화하면서 표적 치료를 가능하게 합니다. 항체 기반 약물의 임상시험과 FDA 승인 증가는 이 부문의 성장을 더욱 촉진할 것입니다.
세계의 생체접합 시장에 대해 조사했으며, 유형별, 기술별, 생체분자 유형별, 용도별, 최종사용자별, 접합 유형별, 지역별 동향, 시장 진출기업 프로파일 등의 정보를 정리하여 전해드립니다.
목차
제1장 서론
제2장 조사 방법
제3장 주요 요약
제4장 프리미엄 인사이트
제5장 시장 개요
- 서론
- 시장 역학
- 고객의 비즈니스에 영향을 미치는 동향/혼란
- 가격 분석
- 공급망 분석
- 밸류체인 분석
- 생태계 분석
- 기술 분석
- 특허 분석
- 2025-2026년 주요 컨퍼런스 및 이벤트
- 규제 분석
- 투자와 자금조달 시나리오
- Porter의 Five Forces 분석
- 주요 이해관계자와 구입 기준
- 무역 분석
- AI/생성형 AI가 생체접합 시장에 미치는 영향
제6장 생체접합 제품 시장(유형별)
제7장 생체접합 제품 시장(기술별)
- 서론
- 화학 결합
- 클릭 케미스트리
- 효소 접합
- 광반응성 가교
- 기타
제8장 생체접합 제품 시장(생체분자 유형별)
- 서론
- 항체
- 펩티드
- 단백질
- 올리고뉴클레오티드
- 기타
제9장 생체접합 제품 시장(용도별)
제10장 생체접합 제품 시장(최종사용자별)
- 서론
- 제약 기업 및 바이오테크놀러지 기업
- CRO 및 CMO
- 학술연구기관
- 병원 및 임상/진단 실험실
제11장 생체접합 서비스 시장(유형별)
- 서론
- 커스텀 합성 및 결합 서비스
- 분석 및 특성 평가 서비스
- 스케일업 및 제조 서비스
- 기타
제12장 생체접합 서비스 시장(공액 유형별)
- 서론
- 항체 결합
- 펩티드 결합
- 단백질 결합
- 올리고뉴클레오티드 결합
- 기타
제13장 생체접합 서비스 시장(기술별)
- 서론
- 화학 결합
- 클릭 케미스트리
- 효소 접합
- 광반응성 가교
- 기타
제14장 생체접합 서비스 시장(용도별)
제15장 생체접합 서비스 시장(최종사용자별)
- 서론
- 제약 기업 및 바이오테크놀러지 기업
- 학술연구기관
- 병원 및 임상/진단 실험실
제16장 생체접합 시장(지역별)
- 서론
- 북미
- 유럽
- 유럽의 거시경제 전망
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 기타
- 아시아태평양
- 아시아태평양의 거시경제 전망
- 중국
- 일본
- 인도
- 한국
- 호주
- 기타
- 라틴아메리카
- 라틴아메리카의 거시경제 전망
- 브라질
- 멕시코
- 기타
- 중동
- 아프리카
- 시장 성장을 지지하기 위해서 대상 환자 풀을 확대
- 아프리카의 거시경제 전망
제17장 경쟁 구도
- 개요
- 주요 시장 진출기업의 전략/강점
- 매출 분석, 2019년-2023년
- 시장 점유율 분석, 2023년
- 기업 평가 매트릭스 : 주요 시장 진출기업, 2023년
- 기업 평가 매트릭스 : 스타트업/중소기업, 2023년
- 기업 평가와 재무 지표
- 브랜드/제품/서비스 비교
- 경쟁 시나리오
제18장 기업 개요
- 주요 시장 진출기업
- DANAHER CORPORATION
- LONZA
- THERMO FISHER SCIENTIFIC INC.
- MERCK KGAA
- ABBVIE INC.
- WUXI BIOLOGICS(CAYMAN) INC.
- SARTORIUS AG
- BIO-RAD LABORATORIES, INC.
- CATALENT, INC.
- BECKTON, DICKINSON AND COMPANY
- AGILENT TECHNOLOGIES, INC.
- PROMEGA CORPORATION
- F. HOFFMANN-LA ROCHE LTD.
- CHARLES RIVER LABORATORIES
- GENSCRIPT BIOTECH CORPORATION
- PIRAMAL PHARMA LIMITED
- 기타 기업
- ABZENA LTD.
- NEW ENGLAND BIOLABS
- BIOSYNTH
- CELL SIGNALING TECHNOLOGY, INC.
- CREATIVE BIOLABS
- FORMOSA LABORATORIES INC.
- NJ BIO, INC.
- ROCKLAND IMMUNOCHEMICALS, INC.
- SHANGHAI CHEMPARTNER
- STERLING PHARMA SOLUTIONS LIMITED
- SYNGENE INTERNATIONAL LIMITED
- TOKYO CHEMICAL INDUSTRY CO., LTD.
- VECTOR LABORATORIES, INC.
제19장 부록
LSH
The bioconjugation market is expected to grow to USD 10.86 billion by 2029, up from USD 5.27 billion in 2024, at a CAGR of 15.6% between 2024 and 2029. Several key factors impact the growth of the bioconjugation market. The development of targeted therapeutics such as ADCs is expected to be greatly supported by bioconjugation, as the need for more accurate and potent cancer treatments grows. Furthermore, there is a growing focus on technological developments and outsourcing services. Furthermore, emerging countries provide significant development opportunities, and the expanding applications of bioconjugation are expected to drive the market further.
| Scope of the Report |
|---|
| Years Considered for the Study | 2022-2029 |
| Base Year | 2023 |
| Forecast Period | 2024-2029 |
| Units Considered | Value (USD) |
| Segments | By Products, and Services |
| Regions covered | North America, Europe, Asia Pacific, Latin America, Middle East, and Africa |
"The antibody conjugation segment accounted for the largest share of by conjugation type segment for the bioconjugation services market in 2023."
In 2023, the antibody conjugation segment accounted for the largest share of the global bioconjugation services market by conjugation type. The antibody conjugation segment dominates the bioconjugation services market because it is widely used in developing targeted treatments, particularly for cancer. Antibody-drug conjugates (ADCs) enable accurate drug delivery by targeting specific antigens on tumor cells, minimizing off-target effects and toxicity. The favourable results of ADCs in clinical trials, as well as their approval to treat a variety of malignancies, including HER2-positive breast cancer, have increased demand for antibody-based conjugation services.
"The antibodies segment accounted for the largest share of by biomolecule type segment for the bioconjugation products market in 2023."
In 2023, the antibodies segment accounted for the largest share of the global bioconjugation products market by biomolecule type. The most prominent biomolecule type in the bioconjugation products market is antibodies, especially monoclonal antibodies, which are dominantly used in the development of Antibody-Drug Conjugates (ADCs) with higher accuracy in targeting. Antibodies are integrally used in oncology and have led to several FDA-approved ADC therapies such as Adcetris and Kadcyla. These therapeutic antibodies conjugated with cytotoxic drugs through bioconjugation techniques allow for targeted treatment while minimizing systemic toxicity. Increasing clinical trials and FDA approvals for the drugs based on antibodies further drive the growth of this segment.
"In 2023, the US remained to dominate the bioconjugation market."
The US dominated the North American bioconjugation market in 2023. The US is the world's largest biopharmaceutical market and the leader in biopharmaceutical research and investment. The United States also has a strong healthcare infrastructure, which encourages research and development in the life sciences. Additionally, the significant presence of many biopharmaceutical companies and growing research activities in the biotechnology industry are propelling market growth in the US. Moreover, the growing prevalence of cancer is also driving the growth of the bioconjugation market.
In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other
executives from various key organizations operating in the bioconjugation
marketplace.
- By Respondent: Supply Side- 70% and Demand Side 30%
- By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
- By Region: North America - 40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%
Danaher Corporation (US); Lonza (Switzerland); Thermo Fisher Scientific Inc. (US); Merck KGaA (Germany); AbbVie Inc. (US); WuXi Biologics (Cayman) Inc. (China); Sartorius AG (Germany); are some of the key players in the bioconjugation market.
The study includes an in-depth competitive analysis of these key players in the bioconjugation market, with their company profiles, recent developments, and key market strategies
Research Coverage:
This research report categorizes the bioconjugation market by product type (consumables { reagents and kits [linker and crosslinking reagents & kits, labeling reagents & kits, modification reagents & kits, other reagents & kits], labels [fluorescent tags, enzymes, haptens, polymers, bead coupling, other labels], other consumables}, instruments {chromatography systems, mass spectrometers, spectroscopy instruments, flow cytometers, electrophoresis equipment, filtration systems, mixers/shakers, incubators, other instruments}]), technique (chemical conjugation, click chemistry, enzyme-mediated conjugation, photoreactive crosslinking, other techniques), biomolecule type (antibodies, peptides, proteins, oligonucleotides, other biomolecules), application (therapeutics {antibody-drug conjugates (ADCs), peptide-drug conjugates, protein-drug conjugates, other therapeutic applications}, research & development, diagnostics), end user (pharmaceutical & biotechnology companies, CROs & CMOs, academic & research institutes, hospitals and clinical/diagnostic laboratories), service type ( custom synthesis & conjugation services, analytical & characterization services, scale-up & manufacturing services, other services), technique (chemical conjugation, click chemistry, enzyme-mediated conjugation, photoreactive crosslinking, other techniques), conjugation type (antibody conjugation, peptide conjugation, protein conjugation, oligonucleotide conjugation, other conjugation services), application (therapeutics, research & development, diagnostics), end user (pharmaceutical & biotechnology companies, academic & research institutes, hospitals and clinical/diagnostic laboratories), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the bioconjugation market. A thorough analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. Also, it includes new product launches, collaborations and acquisitions, and recent developments associated with the bioconjugation market.
Reasons to buy this report
The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall bioconjugation market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (growing demand for targeted therapies, increasing investments in biopharmaceutical R&D, rising demand for outsourcing services, expanding pipeline of bioconjugated drugs, advancements in bioconjugation technologies), restraints (high cost of bioconjugate development & manufacturing, stringent regulatory requirements), opportunities (high growth potential of emerging economies, expanding applications of bioconjugation), and Challenges (technical complexities) influencing the growth of the market.
- Product/Service Development/Innovation: Detailed insights on newly launched products/services of the bioconjugation market
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the bioconjugation market
- Competitive Assessment: In-depth assessment of market shares, growth strategies and product/service offerings of leading players like Danaher Corporation (US), Lonza (Switzerland), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), AbbVie Inc. (US), WuXi Biologics (Cayman) Inc. (China), Sartorius AG (Germany), Bio-Rad Laboratories, Inc. (US), among others in the market.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 MARKET SCOPE
- 1.3.1 MARKETS COVERED
- 1.3.2 INCLUSIONS & EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.3.4 CURRENCY CONSIDERED
- 1.4 MARKET STAKEHOLDERS
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
- 2.1.2 PRIMARY DATA
- 2.2 MARKET ESTIMATION METHODOLOGY
- 2.2.1 MARKET ESTIMATION
- 2.2.2 INSIGHTS FROM PRIMARY EXPERTS
- 2.2.3 TOP-DOWN APPROACH
- 2.3 MARKET GROWTH RATE PROJECTION
- 2.4 DATA TRIANGULATION
- 2.5 RESEARCH ASSUMPTIONS
- 2.6 RESEARCH LIMITATIONS
- 2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 BIOCONJUGATION MARKET OVERVIEW
- 4.2 NORTH AMERICA: BIOCONJUGATION PRODUCTS MARKET, BY APPLICATION AND COUNTRY (2023)
- 4.3 BIOCONJUGATION PRODUCTS MARKET, BY TYPE (2023)
- 4.4 BIOCONJUGATION PRODUCTS MARKET, BY END USER (2023)
- 4.5 BIOCONJUGATION SERVICES MARKET, BY TYPE (2023)
- 4.6 BIOCONJUGATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 Growing demand for targeted therapies
- 5.2.1.2 Increasing investments in biopharmaceutical R&D
- 5.2.1.3 Rising demand for outsourcing services
- 5.2.1.4 Expanding pipeline of bioconjugate drugs
- 5.2.1.5 Advancements in bioconjugation technologies
- 5.2.2 RESTRAINTS
- 5.2.2.1 High cost of bioconjugate development & manufacturing
- 5.2.2.2 Stringent regulatory requirements
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 High growth potential of emerging economies
- 5.2.3.2 Expanding applications of bioconjugation
- 5.2.4 CHALLENGES
- 5.2.4.1 Technical complexities
- 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- 5.4 PRICING ANALYSIS
- 5.4.1 INDICATIVE PRODUCT PRICING ANALYSIS, BY KEY PLAYER
- 5.4.2 INDICATIVE PRODUCT PRICING ANALYSIS, BY REGION
- 5.5 SUPPLY CHAIN ANALYSIS
- 5.6 VALUE CHAIN ANALYSIS
- 5.7 ECOSYSTEM ANALYSIS
- 5.7.1 BIOCONJUGATION MARKET: RAW MATERIAL SUPPLIERS
- 5.7.2 BIOCONJUGATION MARKET: PRODUCT MANUFACTURERS
- 5.7.3 BIOCONJUGATION MARKET: SERVICE PROVIDERS
- 5.7.4 BIOCONJUGATION MARKET: END USERS
- 5.7.5 BIOCONJUGATION MARKET: REGULATORY BODIES
- 5.8 TECHNOLOGY ANALYSIS
- 5.8.1 KEY TECHNOLOGIES
- 5.8.1.1 Chemical conjugation
- 5.8.1.2 Enzymatic conjugation
- 5.8.1.3 Photochemical conjugation
- 5.8.1.4 Click chemistry
- 5.8.2 COMPLEMENTARY TECHNOLOGIES
- 5.8.3 ADJACENT TECHNOLOGIES
- 5.9 PATENT ANALYSIS
- 5.10 KEY CONFERENCES & EVENTS, 2025-2026
- 5.11 REGULATORY ANALYSIS
- 5.11.1 REGULATORY LANDSCAPE
- 5.11.1.1 North America
- 5.11.1.1.1 US
- 5.11.1.1.2 Canada
- 5.11.1.2 Europe
- 5.11.1.2.1 Germany
- 5.11.1.2.2 UK
- 5.11.1.3 Asia Pacific
- 5.11.1.3.1 Japan
- 5.11.1.3.2 China
- 5.11.1.4 Latin America
- 5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.12 INVESTMENT & FUNDING SCENARIO
- 5.13 PORTER'S FIVE FORCES ANALYSIS
- 5.13.1 THREAT OF NEW ENTRANTS
- 5.13.2 THREAT OF SUBSTITUTES
- 5.13.3 BARGAINING POWER OF BUYERS
- 5.13.4 BARGAINING POWER OF SUPPLIERS
- 5.13.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
- 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.14.2 BUYING CRITERIA FOR END USERS
- 5.15 TRADE ANALYSIS
- 5.16 IMPACT OF AI/GENERATIVE AI ON BIOCONJUGATION MARKET
6 BIOCONJUGATION PRODUCTS MARKET, BY TYPE
- 6.1 INTRODUCTION
- 6.2 CONSUMABLES
- 6.2.1 REAGENTS & KITS
- 6.2.1.1 Linker and crosslinking reagents & kits
- 6.2.1.1.1 Precision in conjugation reactions to boost demand
- 6.2.1.2 Labeling reagents & kits
- 6.2.1.2.1 Growing demand for enhanced diagnostic sensitivity to fuel uptake
- 6.2.1.3 Modification reagents & kits
- 6.2.1.3.1 Uptake of protein engineering for optimal behavior to support market growth
- 6.2.1.4 Other reagents & kits
- 6.2.2 LABELS
- 6.2.2.1 Fluorescent tags
- 6.2.2.1.1 Rising demand in imaging & diagnostics to drive market
- 6.2.2.2 Enzymes
- 6.2.2.2.1 Increasing utilization of western blotting & ELISA kits to fuel market
- 6.2.2.3 Haptens
- 6.2.2.3.1 Wide applications in immunoassays and vaccine development to support market growth
- 6.2.2.4 Polymers
- 6.2.2.4.1 Advancements in polymer-based drug delivery systems to drive market
- 6.2.2.5 Bead coupling
- 6.2.2.5.1 Utilization in magnetic bead-based immunoassays and cell separation to support market growth
- 6.2.2.6 Other labels
- 6.2.3 OTHER CONSUMABLES
- 6.3 INSTRUMENTS
- 6.3.1 CHROMATOGRAPHY SYSTEMS
- 6.3.1.1 Ability to offer precision and purification to drive market
- 6.3.2 MASS SPECTROMETERS
- 6.3.2.1 High uptake in bioconjugate characterization to drive market
- 6.3.3 SPECTROSCOPY INSTRUMENTS
- 6.3.3.1 Monitoring of bioconjugation reactions in real-time to fuel uptake
- 6.3.4 FLOW CYTOMETERS
- 6.3.4.1 Determination of therapeutic potential in ADCs to propel market
- 6.3.5 ELECTROPHORESIS EQUIPMENT
- 6.3.5.1 Increasing requirement for reliable analysis to support market growth
- 6.3.6 FILTRATION SYSTEMS
- 6.3.6.1 High purity requirements to support market growth
- 6.3.7 MIXERS & SHAKERS
- 6.3.7.1 Ability to ensure uniform conjugation reactions to boost demand
- 6.3.8 INCUBATORS
- 6.3.8.1 Integration of smart technologies for controlled environments to drive market
- 6.3.9 OTHER INSTRUMENTS
7 BIOCONJUGATION PRODUCTS MARKET, BY TECHNIQUE
- 7.1 INTRODUCTION
- 7.2 CHEMICAL CONJUGATION
- 7.2.1 HIGH DEMAND FOR ONCOLOGY ADCS AND VERSATILE TECHNIQUE TO PROPEL MARKET
- 7.3 CLICK CHEMISTRY
- 7.3.1 GROWING NEED FOR REGULATORY COMPLIANCE AND QUALITY ASSURANCE TO PROPEL MARKET
- 7.4 ENZYME-MEDIATED CONJUGATION
- 7.4.1 INCREASING NUMBER OF CLINICAL TRIALS TO BOOST DEMAND
- 7.5 PHOTOREACTIVE CROSSLINKING
- 7.5.1 DEVELOPMENT OF LIGHT-ACTIVATED THERAPEUTICS AND IMAGING AGENTS TO SUPPORT MARKET GROWTH
- 7.6 OTHER TECHNIQUES
8 BIOCONJUGATION PRODUCTS MARKET, BY BIOMOLECULE TYPE
- 8.1 INTRODUCTION
- 8.2 ANTIBODIES
- 8.2.1 EXPANDING THERAPEUTIC APPLICATIONS TO SUPPORT MARKET GROWTH
- 8.3 PEPTIDES
- 8.3.1 HIGH FLEXIBILITY AND DRUG DELIVERY EFFICIENCY TO FUEL UPTAKE
- 8.4 PROTEINS
- 8.4.1 INCREASING DEVELOPMENT OF ELISA AND PDCS IN THERAPEUTIC APPLICATIONS TO DRIVE MARKET
- 8.5 OLIGONUCLEOTIDES
- 8.5.1 GROWING UPTAKE IN GENE THERAPY TO SUPPORT MARKET
- 8.6 OTHER BIOMOLECULES
9 BIOCONJUGATION PRODUCTS MARKET, BY APPLICATION
- 9.1 INTRODUCTION
- 9.2 THERAPEUTICS
- 9.2.1 ANTIBODY-DRUG CONJUGATES
- 9.2.1.1 Increasing demand for targeted cancer therapies to propel market
- 9.2.2 PEPTIDE-DRUG CONJUGATES
- 9.2.2.1 Advancements in peptide synthesis to boost demand
- 9.2.3 PROTEIN-DRUG CONJUGATES
- 9.2.3.1 Improvements in bioavailability and pharmacokinetics of therapeutic agents to drive market
- 9.2.4 OTHER THERAPEUTIC APPLICATIONS
- 9.3 RESEARCH & DEVELOPMENT
- 9.3.1 GROWING INTEREST IN INNOVATIVE THERAPEUTIC MODALITIES TO DRIVE MARKET
- 9.4 DIAGNOSTICS
- 9.4.1 UTILIZATION IN DIAGNOSTIC ASSAY DEVELOPMENT TO SUPPORT MARKET GROWTH
10 BIOCONJUGATION PRODUCTS MARKET, BY END USER
- 10.1 INTRODUCTION
- 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 10.2.1 INCREASING ADOPTION OF BIOCONJUGATION IN TARGETED THERAPIES TO DRIVE MARKET
- 10.3 CONTRACT RESEARCH ORGANIZATIONS (CROS) & CONTRACT MANUFACTURING ORGANIZATIONS (CMOS)
- 10.3.1 INCREASING OUTSOURCING OF BIOCONJUGATION SERVICES TO PROPEL MARKET
- 10.4 ACADEMIC & RESEARCH INSTITUTES
- 10.4.1 INCREASING FOCUS ON NOVEL BIOCONJUGATION TECHNIQUES FOR BASIC & APPLIED RESEARCH TO FUEL UPTAKE
- 10.5 HOSPITALS AND CLINICAL/DIAGNOSTIC LABORATORIES
- 10.5.1 EXPANDING APPLICATIONS OF BIOCONJUGATES IN DIAGNOSTICS & THERAPEUTICS TO SUPPORT MARKET GROWTH
11 BIOCONJUGATION SERVICES MARKET, BY TYPE
- 11.1 INTRODUCTION
- 11.2 CUSTOM SYNTHESIS & CONJUGATION SERVICES
- 11.2.1 GROWING NEED FOR TARGETED & CUSTOMIZED THERAPIES TO DRIVE MARKET
- 11.3 ANALYTICAL & CHARACTERIZATION SERVICES
- 11.3.1 GROWING FOCUS ON REGULATORY COMPLIANCE TO FUEL UPTAKE
- 11.4 SCALE-UP & MANUFACTURING SERVICES
- 11.4.1 INCREASING COMMERCIALIZATION OF BIOCONJUGATED DRUGS TO SUPPORT MARKET GROWTH
- 11.5 OTHER SERVICES
12 BIOCONJUGATION SERVICES MARKET, BY CONJUGATION TYPE
- 12.1 INTRODUCTION
- 12.2 ANTIBODY CONJUGATION
- 12.2.1 ABILITY TO LINK ANTIBODIES TO PAYLOADS FOR SPECIALIZED THERAPEUTICS TO PROPEL MARKET
- 12.3 PEPTIDE CONJUGATION
- 12.3.1 IMPROVED STABILITY & BIOAVAILABILITY TO DRIVE MARKET
- 12.4 PROTEIN CONJUGATION
- 12.4.1 LINKING PROTEINS WITH DRUGS FOR TARGETED DELIVERY TO FUEL UPTAKE
- 12.5 OLIGONUCLEOTIDE CONJUGATION
- 12.5.1 ADVANCEMENTS IN NUCLEIC ACID-BASED THERAPEUTICS TO SUPPORT MARKET GROWTH
- 12.6 OTHER CONJUGATION SERVICES
13 BIOCONJUGATION SERVICES MARKET, BY TECHNIQUE
- 13.1 INTRODUCTION
- 13.2 CHEMICAL CONJUGATION
- 13.2.1 ESSENTIAL TECHNIQUE FOR DEVELOPMENT OF CUSTOM BIOCONJUGATES TO FUEL UPTAKE
- 13.3 CLICK CHEMISTRY
- 13.3.1 PROVISION OF HIGH YIELD FOR DEVELOPMENT OF COMPLEX BIOCONJUGATES TO PROPEL MARKET
- 13.4 ENZYME-MEDIATED CONJUGATION
- 13.4.1 NEED FOR PRECISE & STABLE CONJUGATES IN COMPLEX THERAPEUTIC MODALITIES TO DRIVE MARKET
- 13.5 PHOTOREACTIVE CROSSLINKING
- 13.5.1 ABILITY TO PROVIDE CONTROLLED & SITE-SPECIFIC FORMATION OF CROSSLINKS TO SUPPORT MARKET GROWTH
- 13.6 OTHER TECHNIQUES
14 BIOCONJUGATION SERVICES MARKET, BY APPLICATION
- 14.1 INTRODUCTION
- 14.2 THERAPEUTICS
- 14.2.1 STRATEGIC PARTNERSHIPS BETWEEN BIOPHARMA COMPANIES AND BIOCONJUGATION SERVICE PROVIDERS TO PROPEL MARKET
- 14.3 RESEARCH & DEVELOPMENT
- 14.3.1 GROWING FOCUS ON BIOMOLECULAR RESEARCH INNOVATION TO DRIVE MARKET
- 14.4 DIAGNOSTICS
- 14.4.1 DEVELOPMENT OF ADVANCED IMAGING TECHNOLOGIES AND BIOSENSORS TO SUPPORT MARKET GROWTH
15 BIOCONJUGATION SERVICES MARKET, BY END USER
- 15.1 INTRODUCTION
- 15.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 15.2.1 ADVANCEMENTS IN DRUG DISCOVERY & DEVELOPMENT TO PROPEL MARKET
- 15.3 ACADEMIC & RESEARCH INSTITUTES
- 15.3.1 INNOVATION IN CONJUGATION TECHNIQUES AND BIOMEDICAL RESEARCH TO DRIVE MARKET
- 15.4 HOSPITALS AND CLINICAL/DIAGNOSTIC LABORATORIES
- 15.4.1 INCREASING DEMAND FOR PRECISION DIAGNOSTICS TO FUEL UPTAKE
16 BIOCONJUGATION MARKET, BY REGION
- 16.1 INTRODUCTION
- 16.2 NORTH AMERICA
- 16.2.1 MACROECONOMIC OUTLOOK OF NORTH AMERICA
- 16.2.2 US
- 16.2.2.1 High healthcare expenditure to propel market
- 16.2.3 CANADA
- 16.2.3.1 Increasing government funding for drug development to support market growth
- 16.3 EUROPE
- 16.3.1 MACROECONOMIC OUTLOOK OF EUROPE
- 16.3.2 GERMANY
- 16.3.2.1 Facility expansion by key players to aid market growth
- 16.3.3 UK
- 16.3.3.1 Increased cancer prevalence and government funding for pharmaceutical & biotechnology research to fuel uptake
- 16.3.4 FRANCE
- 16.3.4.1 Favorable government initiatives and growing demand for personalized therapeutics to boost demand
- 16.3.5 ITALY
- 16.3.5.1 Increasing industrial collaborations for ADC production to support market growth
- 16.3.6 SPAIN
- 16.3.6.1 Growing preference for personalized medicine to drive market
- 16.3.7 REST OF EUROPE
- 16.4 ASIA PACIFIC
- 16.4.1 MACROECONOMIC OUTLOOK OF ASIA PACIFIC
- 16.4.2 CHINA
- 16.4.2.1 Expansion of biopharmaceutical manufacturing facilities to boost demand
- 16.4.3 JAPAN
- 16.4.3.1 Increasing collaborations among biotechnology companies to support market growth
- 16.4.4 INDIA
- 16.4.4.1 High investments in pharma R&D and favorable government policies to boost demand
- 16.4.5 SOUTH KOREA
- 16.4.5.1 Increased focus on quality manufacturing practices to propel market
- 16.4.6 AUSTRALIA
- 16.4.6.1 Growing demand for innovative research solutions to drive market
- 16.4.7 REST OF ASIA PACIFIC
- 16.5 LATIN AMERICA
- 16.5.1 MACROECONOMIC OUTLOOK OF LATIN AMERICA
- 16.5.2 BRAZIL
- 16.5.2.1 Increasing pharmaceutical R&D to fuel market
- 16.5.3 MEXICO
- 16.5.3.1 High FDIs and reduced pharmaceutical manufacturing costs to drive market
- 16.5.4 REST OF LATIN AMERICA
- 16.6 MIDDLE EAST
- 16.6.1 MACROECONOMIC OUTLOOK OF MIDDLE EAST
- 16.6.2 GCC COUNTRIES
- 16.6.2.1 Kingdom of Saudi Arabia
- 16.6.2.1.1 Rising healthcare expenditure to boost market
- 16.6.2.2 United Arab Emirates
- 16.6.2.2.1 Increasing collaborations among biopharma companies to aid market growth
- 16.6.2.3 Other GCC Countries
- 16.6.3 REST OF MIDDLE EAST
- 16.7 AFRICA
- 16.7.1 INCREASING TARGET PATIENT POOL TO SUPPORT MARKET GROWTH
- 16.7.2 MACROECONOMIC OUTLOOK OF AFRICA
17 COMPETITIVE LANDSCAPE
- 17.1 OVERVIEW
- 17.2 KEY PLAYER STRATEGY/RIGHT TO WIN
- 17.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BIOCONJUGATION MARKET
- 17.3 REVENUE ANALYSIS, 2019-2023
- 17.4 MARKET SHARE ANALYSIS, 2023
- 17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
- 17.5.1 STARS
- 17.5.2 EMERGING LEADERS
- 17.5.3 PERVASIVE PLAYERS
- 17.5.4 PARTICIPANTS
- 17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
- 17.5.5.1 Company footprint
- 17.5.5.2 Product/Service footprint
- 17.5.5.3 Application footprint
- 17.5.5.4 End-user footprint
- 17.5.5.5 Region footprint
- 17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
- 17.6.1 PROGRESSIVE COMPANIES
- 17.6.2 RESPONSIVE COMPANIES
- 17.6.3 DYNAMIC COMPANIES
- 17.6.4 STARTING BLOCKS
- 17.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
- 17.7 COMPANY VALUATION & FINANCIAL METRICS
- 17.7.1 FINANCIAL METRICS
- 17.7.2 COMPANY VALUATION
- 17.8 BRAND/PRODUCT/SERVICE COMPARISON
- 17.9 COMPETITIVE SCENARIO
- 17.9.1 PRODUCT/SERVICE LAUNCHES
- 17.9.2 DEALS
- 17.9.3 EXPANSIONS
18 COMPANY PROFILES
- 18.1 KEY PLAYERS
- 18.1.1 DANAHER CORPORATION
- 18.1.1.1 Business overview
- 18.1.1.2 Products/Services offered
- 18.1.1.3 Recent developments
- 18.1.1.3.1 Product/Service launches
- 18.1.1.3.2 Deals
- 18.1.1.3.3 Expansions
- 18.1.1.4 MnM view
- 18.1.1.4.1 Key strengths
- 18.1.1.4.2 Strategic choices
- 18.1.1.4.3 Weaknesses & competitive threats
- 18.1.2 LONZA
- 18.1.2.1 Business overview
- 18.1.2.2 Products/Services offered
- 18.1.2.3 Recent developments
- 18.1.2.3.1 Deals
- 18.1.2.3.2 Expansions
- 18.1.2.4 MnM view
- 18.1.2.4.1 Key strengths
- 18.1.2.4.2 Strategic choices
- 18.1.2.4.3 Weaknesses & competitive threats
- 18.1.3 THERMO FISHER SCIENTIFIC INC.
- 18.1.3.1 Business overview
- 18.1.3.2 Products/Services offered
- 18.1.3.3 Recent developments
- 18.1.3.3.1 Product/Service launches
- 18.1.3.3.2 Deals
- 18.1.3.3.3 Expansions
- 18.1.3.4 MnM view
- 18.1.3.4.1 Key strengths
- 18.1.3.4.2 Strategic choices
- 18.1.3.4.3 Weaknesses & competitive threats
- 18.1.4 MERCK KGAA
- 18.1.4.1 Business overview
- 18.1.4.2 Products/Services offered
- 18.1.4.3 Recent developments
- 18.1.4.3.1 Product/Service launches
- 18.1.4.3.2 Deals
- 18.1.4.3.3 Expansions
- 18.1.4.4 MnM view
- 18.1.4.4.1 Key strengths
- 18.1.4.4.2 Strategic choices
- 18.1.4.4.3 Weaknesses & competitive threats
- 18.1.5 ABBVIE INC.
- 18.1.5.1 Business overview
- 18.1.5.2 Products/Services offered
- 18.1.5.3 Recent developments
- 18.1.5.3.1 Deals
- 18.1.5.3.2 Expansions
- 18.1.5.4 MnM view
- 18.1.5.4.1 Key strengths
- 18.1.5.4.2 Strategic choices
- 18.1.5.4.3 Weaknesses & competitive threats
- 18.1.6 WUXI BIOLOGICS (CAYMAN) INC.
- 18.1.6.1 Business overview
- 18.1.6.2 Products/Services offered
- 18.1.6.3 Recent developments
- 18.1.6.3.1 Deals
- 18.1.6.3.2 Expansions
- 18.1.7 SARTORIUS AG
- 18.1.7.1 Business overview
- 18.1.7.2 Products/Services offered
- 18.1.7.3 Recent developments
- 18.1.7.3.1 Deals
- 18.1.7.3.2 Expansions
- 18.1.8 BIO-RAD LABORATORIES, INC.
- 18.1.8.1 Business overview
- 18.1.8.2 Products/Services offered
- 18.1.9 CATALENT, INC.
- 18.1.9.1 Business overview
- 18.1.9.2 Products/Services offered
- 18.1.9.3 Recent developments
- 18.1.9.3.1 Product/Service launches
- 18.1.9.3.2 Deals
- 18.1.9.3.3 Expansions
- 18.1.10 BECKTON, DICKINSON AND COMPANY
- 18.1.10.1 Business overview
- 18.1.10.2 Products/Services offered
- 18.1.10.3 Recent developments
- 18.1.10.3.1 Product/Service launches
- 18.1.10.3.2 Deals
- 18.1.11 AGILENT TECHNOLOGIES, INC.
- 18.1.11.1 Business overview
- 18.1.11.2 Products/Services offered
- 18.1.11.3 Recent developments
- 18.1.11.3.1 Product/Service launches
- 18.1.11.3.2 Deals
- 18.1.11.3.3 Expansions
- 18.1.12 PROMEGA CORPORATION
- 18.1.12.1 Business overview
- 18.1.12.2 Products/Services offered
- 18.1.13 F. HOFFMANN-LA ROCHE LTD.
- 18.1.13.1 Business overview
- 18.1.13.2 Products/Services offered
- 18.1.14 CHARLES RIVER LABORATORIES
- 18.1.14.1 Business overview
- 18.1.14.2 Products/Services offered
- 18.1.14.3 Recent developments
- 18.1.15 GENSCRIPT BIOTECH CORPORATION
- 18.1.15.1 Business overview
- 18.1.15.2 Products/Services offered
- 18.1.15.3 Recent developments
- 18.1.16 PIRAMAL PHARMA LIMITED
- 18.1.16.1 Business overview
- 18.1.16.2 Products/services offered
- 18.1.16.3 Recent developments
- 18.1.16.3.1 Product/Service launches
- 18.1.16.3.2 Expansions
- 18.2 OTHER PLAYERS
- 18.2.1 ABZENA LTD.
- 18.2.2 NEW ENGLAND BIOLABS
- 18.2.3 BIOSYNTH
- 18.2.4 CELL SIGNALING TECHNOLOGY, INC.
- 18.2.5 CREATIVE BIOLABS
- 18.2.6 FORMOSA LABORATORIES INC.
- 18.2.7 NJ BIO, INC.
- 18.2.8 ROCKLAND IMMUNOCHEMICALS, INC.
- 18.2.9 SHANGHAI CHEMPARTNER
- 18.2.10 STERLING PHARMA SOLUTIONS LIMITED
- 18.2.11 SYNGENE INTERNATIONAL LIMITED
- 18.2.12 TOKYO CHEMICAL INDUSTRY CO., LTD.
- 18.2.13 VECTOR LABORATORIES, INC.
19 APPENDIX
- 19.1 DISCUSSION GUIDE
- 19.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 19.3 CUSTOMIZATION OPTIONS
- 19.4 RELATED REPORTS
- 19.5 AUTHOR DETAILS
